Brief: Cereno Scientific Says Preclinical Data For Drug Candidate Cs585 Showing High Selectivity For The IP Receptor
16/06/2024 07:31
June 16 (Reuters) - Cereno Scientific AB CRNOSb.ST :
* PRECLINICAL DATA FOR CERENO SCIENTIFIC'S DRUG CANDIDATE
CS585
SHOWING HIGH SELECTIVITY FOR THE IP RECEPTOR PRESENTED AT THE
EHA 2024 HYBRID CONGRESS
Source text for Eikon: ID:nWkr9JMrNh
Further company coverage: CRNOSb.ST
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cereno Scientific AB
See all newsBrief: Cereno Scientific Expects Up To 15 Activated Sites By 2026 In Epimode Trial
Brief: Cereno Scientific Reports Positive Results From Study
Brief: Cereno Scientific Q2 Net Sales Sek 0
Sweden's Cereno Scientific Q2 net loss widens, hurt by clinical development costs
Brief: Cereno Scientific Q2 Loss After Financial Items SEK 30.5 Mln